Form 4: MBX director reports 20,000-share purchase at $13.2492

Q: What did MBX (MBX) disclose in this Form 4?

A director reported buying 20,000 shares of common stock on 10/17/2025 at $13.2492 per share.

Q: How many MBX shares are beneficially owned after the trade?

The filing shows 20,000 shares beneficially owned following the transaction.

Q: Was the MBX transaction direct or indirect?

Ownership is indirect , held by the Steven L Hoerter Revocable Trust per the footnote.

Q: What price did the trust pay for MBX shares?

The reported price was $13.2492 per share.

Q: What relationship does the reporting person have to MBX?

The reporting person is a Director of MBX Biosciences.

Q: Does the filer claim full beneficial ownership of the MBX shares?

The filer disclaims beneficial ownership except to the extent of any pecuniary interest, per the footnote.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

MBX Biosciences (MBX) reported an insider purchase by a director. On 10/17/2025, a revocable trust of the reporting person acquired 20,000 shares of common stock at $13.2492 per share (Transaction Code P). Following the transaction, 20,000 shares were beneficially owned indirectly by the trust. The filer notes a disclaimer of beneficial ownership beyond any pecuniary interest, as stated in the footnote.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Hoerter Steven L.

Role Director

Bought 20,000 shs ($265K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20,000	$13.2492	$265K

Holdings After Transaction: Common Stock — 20,000 shares (Indirect, By Trust)

Footnotes (1)

F1. Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/20/2025 - 04:44 PM

FAQ

What did MBX (MBX) disclose in this Form 4?

A director reported buying 20,000 shares of common stock on 10/17/2025 at $13.2492 per share.

How many MBX shares are beneficially owned after the trade?

The filing shows 20,000 shares beneficially owned following the transaction.

Was the MBX transaction direct or indirect?

Ownership is indirect, held by the Steven L Hoerter Revocable Trust per the footnote.

What is the transaction code in the MBX Form 4?

The transaction code is P.

What price did the trust pay for MBX shares?

The reported price was $13.2492 per share.

What relationship does the reporting person have to MBX?

The reporting person is a Director of MBX Biosciences.

Does the filer claim full beneficial ownership of the MBX shares?

The filer disclaims beneficial ownership except to the extent of any pecuniary interest, per the footnote.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoerter Steven L.

(Last)

(First)

(Middle)

C/O MBX BIOSCIENCES INC.

11711 N. MERIDIAN STREET, SUITE 300

(Street)

CARMEL

46032

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MBX Biosciences, Inc. [ MBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/17/2025		P		20,000	A	$13.2492	20,000	I	By Trust⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

	/s/ Richard Bartram, attorney-in-fact	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR